euro-nephrology-2018-scientifictracks

3 / 6

Page 41
conferenceseries.com
Volume 8 Journal of Nephrology & Therapeutics
ISSN: 2161-0959 Euro Nephrology 2018
October 15-16, 2018
October 15-16, 2018 | Warsaw, Poland
22nd European Nephrology Conference
Efficacy and safety of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism:
Real life data
Ioannis Griveas, M Aktsiali, C Andriopoulos and P Sitaras
NEFROIATRIKI Ltd., Greece
S econdary hyperparathyroidism (SHPT), complication of chronic kidney disease, is characterized by disturbances in
mineral metabolism. Calcium-sensing receptor (CaSR) is the main physiological regulator of parathyroid hormone (PTH)
secreation. We tried to evaluate efficacy and safety of etelcalcetide, a new IV calcimimetic in our hemodialysis (HD) population.
We prospectively followed 60 HD patients for a six month period. The primary endpoint of the study was the proportion
of patients with serum intact parathyroid hormone (iPTH) between 200-350 pg/ml until the end of the study period. The
following parameters were determined as secondary efficacy endpoints: Measured and percent changes from baseline in serum
iPTH, Ca, pH, Alb, Hct, Hb, SAP, cardiac function at each time point. The safety and tolerability profiles of etelcalcetide
were assessed based on AEs (advanced encryption standard). After a month of treatment with etelcalcetide, PTH reduced
significantly from 823 pg/mL to 654.8 pg/mL (p<0.05). pH levels were also significantly reduced from 7.28 to 5.04 mg/dl
(p<0.05). Ca levels remained stable after a week of therapy (from 8.68 mg/dl to 8.61 mg/dl, p=NS). In five patients Ca levels
were below 7.5 mg/dl. In three of them Ca levels returned to baseline after a month, in one dose of etelcalcetide reduced, and
one had to stop medication temporarily. None of our patients had GI adverse effects. After 2 months notification, the new
second-generation calcimimetic etelcalcetide effectively reduces PTH, pH with an acceptable safety profile. Hopefully at the
end of our study protocol we will reach to more solid conclusions regarding better control of SHPT.
Biography
Ioannis Griveas, MD, PhD is a Medical Director of Nephrology Department 417 Veterans Army Administration Hospital of Athens (NIMTS), Professor-Consultant Hellenic
Open University, Medical Director of Private Dialysis Unit “Nefroiatriki”, Athens, Greece, Consultant Nephrologist and Lt. Colonel of the Greek Army. He is also the owner
of private renal clinic, Athens-Nephrology. He has more than 152 presentations in Greek and international conferences and 61 publications in Greek and international
journals. He is the Editor-Author of the books “Principles of Renal Medical Procedures” and “Principles of Cellular Immunity in Peritoneal Dialysis Patients”. He has given
more than 40 lectures in Greek and international conferences and he is currently Special Secretary of the board of National Hellenic Society.
Ioannis Griveas et al., J Nephrol Ther 2018, Volume 8
DOI: 10.4172/2161-0959-C6-066